[
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 4,
    "category": "Effective Date"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Exhibit 10.21",
    "bbox": [
      1000,
      117,
      1000,
      130
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
    "bbox": [
      115,
      151,
      1000,
      165
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "would be competitively harmful if publicly disclosed.",
    "bbox": [
      452,
      169,
      879,
      182
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "EXECUTION",
    "bbox": [
      1000,
      208,
      1000,
      219
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "VERSION",
    "bbox": [
      1000,
      225,
      1000,
      239
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "CO-DEVELOPMENT AGREEMENT",
    "bbox": [
      485,
      254,
      846,
      264
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
    "bbox": [
      179,
      279,
      1000,
      294
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
    "bbox": [
      110,
      297,
      1000,
      315
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
    "bbox": [
      111,
      317,
      1000,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
    "bbox": [
      113,
      338,
      1000,
      351
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
    "bbox": [
      113,
      357,
      1000,
      369
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "\"Parties\").",
    "bbox": [
      112,
      374,
      198,
      390
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
    "bbox": [
      181,
      410,
      1000,
      424
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
    "bbox": [
      111,
      429,
      1000,
      443
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
    "bbox": [
      110,
      447,
      820,
      462
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
    "bbox": [
      180,
      483,
      1000,
      497
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
    "bbox": [
      111,
      501,
      1000,
      516
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
    "bbox": [
      112,
      520,
      1000,
      535
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Countries, and to provide global financing for the continued development of the Product..",
    "bbox": [
      113,
      541,
      859,
      553
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
    "bbox": [
      177,
      573,
      1000,
      589
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      114,
      595,
      891,
      607
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "ARTICLE 1 ",
    "bbox": [
      610,
      630,
      723,
      640
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      594,
      667,
      738,
      678
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
    "bbox": [
      179,
      701,
      1000,
      716
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "following terms which will have the following respective meanings:",
    "bbox": [
      112,
      721,
      666,
      736
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
    "bbox": [
      247,
      756,
      1000,
      770
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
    "bbox": [
      114,
      777,
      820,
      790
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
    "bbox": [
      246,
      810,
      1000,
      827
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
    "bbox": [
      111,
      831,
      1000,
      846
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "entity, and in the case",
    "bbox": [
      112,
      850,
      293,
      865
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]